Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
91 EUR | +3,53 % | +3,53 % | -.--% |
Resumen de negocios
- productos farmacéuticos (70,6%): medicamentos de prescripción en las áreas de medicina especializada (59,3% de las ventas netas; para el tratamiento de la esclerosis múltiple, enfermedades neurológicas, enfermedades inflamatorias, enfermedades autoinmunes, enfermedades raras, cánceres y enfermedades hematológicas raras) y medicina general (40,7%; principalmente para el tratamiento de la diabetes y las enfermedades cardiovasculares);
- vacunas humanas (17,4%): vacunas pediátricas, vacunas contra la gripe, la meningitis y la poliomielitis, vacunas de refuerzo y vacunas para viajeros y zonas endémicas;
- productos sanitarios de consumo (12%).
A finales de 2023, el grupo contaba con 54 centros de producción en todo el mundo.
Las ventas netas se distribuyen geográficamente de la siguiente manera: Francia (5,5%), Europa (18,6%), Estados Unidos (43%), Norteamérica (1,6%) y otros (31,3%).
Número de empleados: 86 088
Ventas por actividad
EUR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Biopharma
88,0
%
| 30 688 | 71,4 % | 37 890 | 88,0 % | +23,47 % |
Consumer Healthcare
12,0
%
| 5 080 | 11,8 % | 5 180 | 12,0 % | +1,97 % |
Ventas por región
EUR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
43,0
%
| 18 275 | 42,5 % | 18 512 | 43,0 % | +1,30 % |
Rest of the World
26,1
%
| 8 386 | 19,5 % | 11 254 | 26,1 % | +34,20 % |
Europe
18,6
%
| 7 703 | 17,9 % | 8 013 | 18,6 % | +4,02 % |
China
6,8
%
| 3 123 | 7,3 % | 2 912 | 6,8 % | -6,76 % |
France
5,5
%
| 2 296 | 5,3 % | 2 379 | 5,5 % | +3,61 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01/09/19 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 01/01/22 |
Chief Tech/Sci/R&D Officer | 51 | - | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/16 |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 49 | 11/09/23 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/19 |
Arnaud Delépine
IRO | Public Communications Contact | - | - |
Raj Verma
PRN | Corporate Officer/Principal | - | 01/12/20 |
- | - | ||
Corporate Officer/Principal | 62 | 01/01/15 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01/05/14 |
Lise Kingo
BRD | Director/Board Member | 62 | 28/04/20 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22/05/20 |
Rachel Duan
BRD | Director/Board Member | 52 | 28/04/20 |
Director/Board Member | 61 | 03/05/13 | |
Antoine Yver
BRD | Director/Board Member | 66 | 03/05/22 |
Barbara Lavernos
BRD | Director/Board Member | 56 | 30/04/21 |
Director/Board Member | 58 | 30/04/19 | |
Yann Tran
BRD | Director/Board Member | 58 | 01/05/21 |
Wolfgang Laux
BRD | Director/Board Member | 56 | 01/04/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 1 264 799 969 | 1 101 935 715 ( 87,12 %) | 13 450 388 ( 1,063 %) | 87,12 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
SANOFI 1.28% | 16 245 648 | 1.28% | 1 595 920 473 $ |
SANOFI INDIA LIMITED 60.40% | 13 909 587 | 60.40% | 1 353 934 300 $ |
EUROAPI 29.77% | 28 298 074 | 29.77% | 85 420 566 $ |
MEIRAGTX HOLDINGS PLC 7.39% | 4 697 737 | 7.39% | 28 515 264 $ |
LAVA THERAPEUTICS N.V. 7.30% | 1 919 455 | 7.30% | 6 391 785 $ |
ENENTO GROUP OYJ 0.12% | 29 249 | 0.12% | 545 225 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Chattem, Inc.
Chattem, Inc. Pharmaceuticals: MajorHealth Technology Chattem, Inc. engages in the manufacture of over-the-counter health and beauty care products. It makes anti-dandruff shampoos, medicated skin care, topical pain care, oral care and internal over-the-counter products. The firm distributes its products to mass merchandisers, drugstores and food retail channels. The company was founded by Zeboim Cartter Patten on February 21, 1879 and is headquartered in Bridgewater, NJ. |
Pharmaceuticals: Major
|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. |
Medical Specialties
|
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Aventis, Inc.
| |
Sanofi-Synthélabo Ltd.
Sanofi-Synthélabo Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Synthélabo Ltd. is a pharmaceutical company based in Reading, UK. The British company was founded in 1990 and specializes in manufacturing and distributing solid-dose and pharmaceutical products. |
Pharmaceuticals: Major
|
Sanofi Pasteur, Inc.
Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. |
Pharmaceuticals: Major
|
Sanofi-aventis Ireland Ltd.
Sanofi-aventis Ireland Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Ireland Ltd. manufactures pharmaceutical products for cardiovascular, central nervous system, metabolic disorders, cardiometabolic, oncology, thrombosis, and vaccines. The company is headquartered in Dublin, Ireland. |
Pharmaceuticals: Major
|
Sanofi-Aventis Europe SAS
Sanofi-Aventis Europe SAS Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the private company is Jérôme Contamine. |
Pharmaceuticals: Major
|
Genzyme Therapeutic Products LP
Genzyme Therapeutic Products LP BiotechnologyHealth Technology Part of Sanofi, Genzyme Therapeutic Products LP is a private company that specializes in biological products except diagnostic substances. The company is based in Boston, MA. |
Biotechnology
|
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+21,85 % | 546 mil M | |
-4,77 % | 359 mil M | |
+16,97 % | 323 mil M | |
+5,69 % | 290 mil M | |
+13,68 % | 234 mil M | |
+3,65 % | 198 mil M | |
-11,12 % | 194 mil M | |
+8,08 % | 167 mil M | |
-3,40 % | 157 mil M |
- Bolsa de valores
- Acciones
- Acción SAN
- Acción SANNV
- Empresa Sanofi